SCHEMBL581067

SCHEMBL581067

Cc1c(C(=O)O)ccnc1Cl

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.55
LMNA P02545 2/20 0.55
KDM4C Q9H3R0 3/20 0.45
KDM5A P29375 2/20 0.45
KDM4E B2RXH2 5/20 0.44
ASPH Q12797 1/20 0.44
KDM8 Q8N371 1/20 0.44
MYC P01106 2/20 0.42
SORT1 Q99523 3/20 0.42
FFAR1 O14842 1/20 0.41
DHODH Q02127 1/20 0.41
L3MBTL1 Q9Y468 2/20 0.40
KDM4A O75164 2/20 0.40
RAB9A P51151 1/20 0.40
EGLN1 Q9GZT9 1/20 0.40
HIF1AN Q9NWT6 1/20 0.40
TSHR P16473 2/20 0.39
CASP1 P29466 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
ALDH1A1 P00352 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL6524532 0.98 SMN1; SMN2 (0.53) SMN1; SMN2LMNAKDM4CKDM5AKDM4E
SCHEMBL1119080 0.84 SMN1; SMN2 (0.41) SMN1; SMN2LMNAKDM4CKDM5AKDM4E
SCHEMBL3656546 0.84 LMNA (0.41) SMN1; SMN2LMNAKDM4CKDM5AKDM4E
SCHEMBL27675661 0.82 SIRT3 (0.43) SMN1; SMN2LMNAKDM4EFFAR1L3MBTL1
SCHEMBL30950090 0.79 ATR (0.55) SMN1; SMN2LMNAKDM4CKDM4EL3MBTL1
SCHEMBL5743790 0.79 CASP1 (0.44) SMN1; SMN2LMNASORT1FFAR1L3MBTL1
SCHEMBL3546923 0.79 ATR (0.55) SMN1; SMN2LMNAKDM4CKDM4EL3MBTL1
SCHEMBL353106 0.79 KDM4E (0.47) SMN1; SMN2LMNAKDM4CKDM5AKDM4E
SCHEMBL29486104 0.79 SMN1; SMN2 (0.59) SMN1; SMN2LMNAKDM4CKDM5AKDM4E
SCHEMBL83616 0.79 SMN1; SMN2 (0.59) SMN1; SMN2LMNAKDM4CKDM5AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116373056-A Flexible intelligent wood with responsiveness function, actuator and preparation method 南京林业大学 2023-07-04 CN claimed
EP-4725942-A1 COMPOUNDS ACTIVE ON CYCLIN D1 PATHWAY AND THEIR USE Sibylla Biotech S.p.A. (IT) 2026-04-15 EP disclosed
US-11976075-B2 Inhibitors of the MYST family of lysine acetyl transferases Isosterix, Inc. 2024-05-07 US disclosed
US-20230416260-A1 Inhibitors of the MYST Family of Lysine Acetyl Transferases Isosterix, Inc. 2023-12-28 US disclosed
WO-2023192817-A1 INHIBITORS OF THE MYST FAMILY OF LYSINE ACETYL TRANSFERASES Isosterix, Inc. (US) 2023-10-05 WO disclosed
US-20230303580-A1 INHIBITORS OF THE MYST FAMILY OF LYSINE ACETYL TRANSFERASES Isosterix, Inc. 2023-09-28 US disclosed
CN-113248492-B Heterocycle substituted nitrogen-containing six-membered heterocyclic derivative, preparation method and medical application thereof 上海海雁医药科技有限公司 2022-11-08 CN disclosed
EP-3943485-A1 ARYL- OR HETEROARYL-SUBSTITUTED BENZENE COMPOUNDS Epizyme, Inc. (US) 2022-01-26 EP disclosed
US-10947242-B2 [1,2,4]triazolo[1,5and#8208;A]pyrimidine compounds as PDE2 inhibitors JANSSEN PHARMACEUTICA, NV (BE) 2021-03-16 US disclosed
EP-3535267-B1 [1,2,4]TRIAZOLO[1,5-A]PYRIMIDINE DERIVATIVES AS PDE2 INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2020-12-30 EP disclosed
WO-2010149684-A1 NEW COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS RELATING THERETO BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-12-29 WO disclosed
WO-2010117323-A1 METHOD AND APPARATUS FOR PRODUCING HEAT ENERGY AND CARBON DIOXIDE ASTRAZENECA AB (SE) 2010-10-14 WO disclosed
US-20100261755-A1 ISOXAZOL-3(2H)-ONE ANALOGS AS THERAPEUTIC AGENTS ASTRAZENECA AB (SE) 2010-10-14 US disclosed
US-7674795-B2 Fluorene derivatives, composition containing said derivatives and the use thereof AVENTIS PHARMA SA (FR) 2010-03-09 US disclosed
WO-2010008739-A2 ARYL GPR119 AGONISTS AND USES THEREOF METABOLEX, INC. (US) 2010-01-21 WO disclosed
WO-2009135944-A1 TRISUBSTITUTED PYRAZOLES AS ACETYLCHOLINE RECEPTOR MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2009-11-12 WO disclosed
US-20080153837-A1 Novel Fluorene Derivatives, Composition Containing Said Derivatives and the Use Thereof AVENTIS PHARMA S.A. (FR) 2008-06-26 US disclosed
US-6509361-B1 Inhibit the activity of p38 MAP kinase. Also contemplated by the invention are processes for the preparation of the contemplated compounds and for the use of a contemplated compound in treating a mammalian host having a p38 kinase or PHARMACIA CORPORATION 2003-01-21 US disclosed
EP-1077971-A1 1,5-DIARYL SUBSTITUTED PYRAZOLES AS p38 KINASE INHIBITORS G.D. SEARLE & CO. (US) 2001-02-28 EP disclosed
WO-1999058523-A1 1,5-DIARYL SUBSTITUTED PYRAZOLES AS p38 KINASE INHIBITORS G.D. SEARLE & CO. (US) 1999-11-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230416260-A1 Inhibitors of the MYST Family of Lysine Acetyl Transferases KAT6A, KAT6B, KAT2A SMN1; SMN2 4266/4885LMNA 2088/4885KDM4C 333/4885
US-20230303580-A1 INHIBITORS OF THE MYST FAMILY OF LYSINE ACETYL TRANSFERASES KAT6A, KAT6B, KAT2A SMN1; SMN2 4266/4885LMNA 2088/4885KDM4C 333/4885
US-11976075-B2 Inhibitors of the MYST family of lysine acetyl transferases KAT6A, KAT6B, KAT2A SMN1; SMN2 4266/4885LMNA 2088/4885KDM4C 333/4885
US-10947242-B2 [1,2,4]triazolo[1,5and#8208;A]pyrimidine compounds as PDE2 inhibitors PDE2A, PDE12, PDE5A SMN1; SMN2 785/4885LMNA 3213/4885KDM4C 1330/4885
US-20100261755-A1 ISOXAZOL-3(2H)-ONE ANALOGS AS THERAPEUTIC AGENTS NR4A3, CBR3, OXER1 SMN1; SMN2 2619/4885LMNA 3853/4885KDM4C 1355/4885
US-20080153837-A1 Novel Fluorene Derivatives, Composition Containing Said Derivatives and the Use Thereof HSP90B1, HSP90AB1, HSP90AA1 SMN1; SMN2 1564/4885LMNA 3461/4885KDM4C 4322/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.